A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms APPEASE
- 19 Jun 2018 Planned End Date changed from 1 May 2023 to 1 Jun 2023.
- 19 Jun 2018 Planned primary completion date changed from 1 May 2023 to 1 Jun 2023.
- 19 Jun 2018 Status changed from not yet recruiting to recruiting, according to a LSK Biopharma media release.